Related Experiment Video
Updated: Apr 15, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Adoptive cellular therapy: a race to the finish line
Carl H June1, Stanley R Riddell2, Ton N Schumacher3
1Center for Cellular Immunotherapies and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
Abstract:
Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of synthetic biology, advances in cell culture and genetic engineering have made it possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. The prospects for widespread availability of engineered T cells have changed dramatically, given the recent entry of the pharmaceutical industry to this arena. Here, we discuss some of the challenges--such as regulatory, cost, and manufacturing--and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy.
Related Concept Videos
Tumor Immunotherapy
Forced Transdifferentiation
Artificial...
iPS Cell Differentiation
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Gene Therapy
Cell-mediated Immune Responses

